← Patent-cliff monitor small molecule ZENBEXUS IBERDOMIDE HYDROCHLORIDE
Loss of exclusivity September 2039 latest FDA-listed patent expiry
Company BRISTOL MYERS SQUIBB CO
Drug detail Brand name ZENBEXUS Active ingredient IBERDOMIDE HYDROCHLORIDE Strength EQ 0.75MG BASE Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval August 2026 Marketing status RX
Listed patents Patent Expires Type 11529339 September 2039 use U-4598 RE50917 October 2034 use U-4598 RE49647 October 2034 product 9221788 September 2033 substance 9629849 August 2033 use U-4598 8518972 June 2031 substance, product 9828361 February 2031 substance, product
Regulatory exclusivity Code Expires NCE August 2031
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.